Empagliflozin

DRUG INFORMATION

  ADULT
    - ( 2.1 ) • Recommended dosage is 10 mg orally once daily in the morning, taken with
      or without food.
      Source: US FDA label for empagliflozin (Jardiance), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 2.2 ) • For additional glycemic control, dosage may be increased to 25 mg orally
      once daily in patients tolerating JARDIANCE.
      Source: US FDA label for empagliflozin (Jardiance), section 'dosage and
      administration', retrieved 2026-08-29
    - Table 1 Recommended Dosage of JARDIANCE Population Indication Recommended Dosage
      Adults Reduce the risk of cardiovascular death and hospitalization in patients
      with heart failure • 10 mg orally once daily in the morning, taken with or without
      food.
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for empagliflozin
      (Jardiance), section 'dosage and administration', retrieved 2026-08-29

  CHILD
    - • Assess renal function before initiating and as clinically indicated. Assess
      volume status and correct volume depletion before initiating. ( 2.1 ) •
      Recommended dosage is 10 mg orally once daily in the morning, taken with or
      without food. ( 2.2 ) • For additional glycemic control, dosage may be increased
      to 25 mg orally once daily in patients tolerating JARDIANCE.
      Source: US FDA label for empagliflozin (Jardiance), section 'dosage and
      administration', retrieved 2026-08-29
    - Pediatric patients aged 10 years and older Glycemic control in type 2 diabetes
      mellitus • 10 mg orally once daily in the morning, taken with or without food. •
      For additional glycemic control, may increase to 25 mg orally once daily in
      patients tolerating 10 mg once daily. 2.3 Temporary Interruption for Surgery
      Withhold JARDIANCE for at least 3 days, if possible, prior to surgery or
      procedures associated with prolonged fasting.
      Source: US FDA label for empagliflozin (Jardiance), section 'dosage and
      administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - ( 2.3 ) 2.1 Testing Prior to Initiation of JARDIANCE • Assess renal function
      before initiating JARDIANCE and as clinically indicated [see Warnings and
      Precautions (5.2) ] . o Use for glycemic control is not recommended in patients
      with an eGFR less than 30 mL/min/1.73 m 2 [see Use in Specific Populations (8.6)
      ]. • Assess volume status.
      Source: US FDA label for empagliflozin (Jardiance), section 'dosage and
      administration', retrieved 2026-08-29
    - Reduce the risk of sustained decline in eGFR, end-stage kidney disease,
      cardiovascular death, and hospitalization in adults with chronic kidney disease at
      risk of progression.
      Source: US FDA label for empagliflozin (Jardiance), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 8.5 ) • Renal Impairment: Higher incidence of adverse reactions related to
      reduced renal function.
      Source: US FDA label for empagliflozin (Jardiance), section 'use in specific
      populations', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - Once enrolled, adult patients in the EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-
      Preserved, and EMPA-KIDNEY trials were not required to discontinue therapy for
      worsening of eGFR to less than 20 mL/min/1.73 m 2 or initiation of dialysis [see
      Clinical Studies (14.3 , 14.4 , 14.5) ]. 8.7 Hepatic Impairment JARDIANCE may be
      used in patients with hepatic impairment [see Clinical Pharmacology (12.3) ] .
      Source: US FDA label for empagliflozin (Jardiance), section 'use in specific
      populations', retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Based on animal data showing adverse renal effects, JARDIANCE is not
      recommended during the second and third trimesters of pregnancy.
      Source: US FDA label for empagliflozin (Jardiance), section 'pregnancy', retrieved
      2026-08-29
    - The limited available data with JARDIANCE in pregnant women are not sufficient to
      determine a drug-associated risk for major birth defects and miscarriage.
      Source: US FDA label for empagliflozin (Jardiance), section 'pregnancy', retrieved
      2026-08-29
    - There are risks to the mother and fetus associated with poorly controlled diabetes
      in pregnancy [see Clinical Considerations ] .
      Source: US FDA label for empagliflozin (Jardiance), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - ( 8.1 ) • Lactation: Not recommended when breastfeeding.
      Source: US FDA label for empagliflozin (Jardiance), section 'use in specific
      populations', retrieved 2026-08-29
    - In pre- and postnatal development studies in pregnant rats, empagliflozin was
      administered from gestation day 6 through to lactation day 20 (weaning) at up to
      100 mg/kg/day (approximately 16-times the 25 mg maximum clinical dose) without
      maternal toxicity.
      Source: US FDA label for empagliflozin (Jardiance), section 'use in specific
      populations', retrieved 2026-08-29
    - Reduced body weight was observed in the offspring at greater than or equal to 30
      mg/kg/day (approximately 4-times the 25 mg maximum clinical dose). 8.2 Lactation
      Risk Summary There is limited information regarding the presence of JARDIANCE in
      human milk, the effects of JARDIANCE on the breastfed infant or the effects on
      milk production.
      Source: US FDA label for empagliflozin (Jardiance), section 'use in specific
      populations', retrieved 2026-08-29